ArticleCurrent treatment options in gastroenterology2015
Gastric Hypersecretory States: Investigation and Management.
Article in Current treatment options in gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder.Microbiology (Reading, England) · 2025Pooled it
- Lactiplantibacillus plantarum DS1073 protects the gastric mucosa under Helicobacter pylori infection and ethanol stress.Cell communication and signaling : CCS · 2026Article
- Both pathogen and host dynamically adapt pH responses along the intestinal tract during enteric bacterial infection.PLoS biology · 2024Article
- Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin BInternational journal of molecular sciences · 2024Article
- Article
- Gastric Cancer Risk Was Associated with Dietary Factors Irritating the Stomach Wall: A Case-Control Study in Korea.Nutrients · 2022Article
- Sham Feeding Induced Gastric Acid Secretion in Patients with Caustic Induced Esophageal Stricture.Dysphagia · 2022Article
- Phenytoin Toxicity with High Dose, Concomitant Ascorbic Acid Dosing.Innovations in pharmacy · 2022Article
- Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.World journal of gastroenterology · 2021Review
- Gastroesophageal Reflux Disease and Foregut Dysmotility in Children with Intestinal Failure.Nutrients · 2020Review
- Advances in CaExperimental and therapeutic medicine · 2020Review
- Non-invasive method for the assessment of gastric acid secretion.Acta bio-medica : Atenei Parmensis · 2018Article
- Presence and Effects of Pituitary Adenylate Cyclase Activating Polypeptide Under Physiological and Pathological Conditions in the Stomach.Frontiers in endocrinology · 2018Review
- Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Digestive diseases and sciences · 2017Review
- The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors.Current gastroenterology reports · 2017Review
- Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.International journal of endocrine oncology · 2017Article
- Autoimmune atrophic gastritis: current perspectives.Clinical and experimental gastroenterology · 2017Review
- Skeletal Fluorosis: A Case of Inhalant Abuse Leading to a Diagnosis of Colon Cancer.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
opinion statementHypersecretory conditions affecting the stomach account for significant morbidity and mortality manifested in some cases with peptic ulcer, gastrointestinal hemorrhage, and/or gastroesophageal reflux disease (GERD). The diagnosis of gastric acid hypersecretory states can be challenging and relies on the use of quantitative assays to measure gastric acid secretion and serum gastrin. The most common etiology for hypergastrinemia is the use of potent gastric acid inhibitors such as the proton pump inhibitors. The differential diagnosis of this condition is of critical importance, and will dictate management decisions. Conditions such as atrophic gastritis are relatively benign and can lead to hypergastrinemia without the presence of gastric acid hypersecretion. Zollinger-Ellison syndrome, on the other hand, causes hypergastrinemia with profound gastric acid hypersecretion [1]. More common causes of hypergastrinemia include gastric outlet obstruction, ileus, and chronic renal failure [2]. In most cases, proton pump inhibitors will be used to manage these conditions. In some instances, surgical therapy may be required. This chapter will review the important clinical causes of gastric acid hypersecretion and provide insights to the best medical management options to better care for patients with these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.